The mechanisms that regulate hematopoietic stem cell (HSC) regeneration after myelosuppressive injury are not well understood. We identified epidermal growth factor (EGF) to be highly enriched in the bone marrow serum of mice bearing deletion of Bak and Bax in TIE2-expressing cells in Tie2Cre; Bak1 -/-; Bax flox/mice. These mice showed radioprotection of the HSC pool and 100% survival after a lethal dose of total-body irradiation (TBI). Bone marrow HSCs from wild-type mice expressed functional EGF receptor (EGFR), and systemic administration of EGF promoted the recovery of the HSC pool in vivo and improved the survival of mice after TBI. Conversely, administration of erlotinib, an EGFR antagonist, decreased both HSC regeneration and the survival of mice after TBI. Mice with EGFR deficiency in VAV-expressing hematopoietic cells also had delayed recovery of bone marrow stem and progenitor cells after TBI. Mechanistically, EGF reduced radiation-induced apoptosis of HSCs and mediated this effect through repression of the proapoptotic protein PUMA. Our findings show that EGFR signaling regulates HSC regeneration after myelosuppressive injury. npg
a r t i c l e s HSCs can be found in proximity to bone marrow sinusoidal vessels 1 , and bone marrow endothelial cells regulate HSC homeostasis and regeneration [2] [3] [4] [5] [6] [7] [8] . It has been previously reported that maintenance of the HSC pool in mice is dependent on the expression of stem cell factor by bone marrow endothelial or perivascular cells, demonstrating the important role of endothelial and perivascular cells in maintaining the HSC pool during homeostasis 8 . We have shown that adult sources of endothelial cells produce soluble growth factors that promote the expansion of human HSCs in vitro 2 and support the regeneration of mouse and human HSCs in vitro after radiation exposure 2, 3, [9] [10] [11] . We have also demonstrated that systemic infusion of autologous or allogeneic endothelial cells accelerates bone marrow HSC reconstitution and hematologic recovery in mice after radiation-induced myelosuppression 4, 12 . A previous study demonstrated a requirement for vascular endothelial growth factor receptor 2 (VEGFR2)-expressing sinusoidal endothelial cells for normal hematologic recovery after TBI 6 . Similarly, systemic delivery of an antibody to vascular endothelial cadherin (VE-cadherin), which inhibits bone marrow vasculogenesis, substantially delays hematologic recovery after myelosuppression 4, 5 . However, the precise mechanisms through which bone marrow endothelial cells regulate hematopoietic regeneration remain unknown.
Here, using a screen for cytokines in the bone marrow serum from Tie2Cre; Bak1 -/-; Bax flox/mice, which lack BAK and BAX in TIE2expressing endothelial cells 13 and show a strong radioprotective phenotype, we identify EGF as a candidate endothelial cell-derived mediator of radioprotection of the hematopoietic system and show that EGFR signaling regulates hematopoietic regeneration in vivo.
Notably, systemic administration of EGF accelerated the recovery of long-term HSCs and improved the survival of mice after radiationinduced myelosuppression, whereas pharmacologic inhibition or genetic deficiency of EGFR antagonized hematopoietic regeneration in vivo.
RESULTS

EGF mediates HSC regeneration in vitro
We previously developed a genetic model to delete the genes encoding BAK and BAX, which regulate the intrinsic pathway of apoptosis 13 , in TIE2-expressing endothelial cells as a means to protect bone marrow endothelial cells from radiation-induced injury 14 . After high-dose TBI, Tie2Cre; Bak1 -/-; Bax flox/mice showed protection of the bone marrow vascular and HSC compartments as well as marked improvement in survival of the mice compared to Tie2Cre; Bak1 -/-; Bax flox/+ mice, which retain one allele of Bax, or compared to wild-type mice 14 .
To identify secreted factors produced by TIE2-expressing bone marrow endothelial cells that might contribute to the radioprotection observed in Tie2Cre; Bak1 -/-; Bax flox/mice, we generated primary bone marrow endothelial cell lines (CD45 -, von Willebrand factor (VWF) + , lectin + and acetylated low-density lipoprotein (AcLDL) + ) from Tie2Cre; Bak1 -/-; Bax flox/mice (FL/-endothelial cells) and Tie2Cre; Bak1 -/-; Bax flox/+ mice (FL/+ endothelial cells), as previously described 2, 3, 9, 15 . When we irradiated wild-type bone marrow c-Kit + Sca-1 + Lin -(KSL) progenitor cells with 300 cGy in vitro and then plated them in noncontact culture with FL/-endothelial cells, a r t i c l e s we found significant increases in the recovery of total cells, colonyforming cells (CFCs) and colony-forming units, spleen, day 12 (CFU-S12) at day +7 compared to when we plated them in noncontact FL/+ endothelial cell cultures (Fig. 1a) . These results suggest that bone marrow endothelial cells from Tie2Cre; Bak1 -/-; Bax flox/mice produce soluble factors that promote hematopoietic stem and progenitor cell regeneration after radiation injury. In a complementary experiment, the addition of bone marrow serum from irradiated Tie2Cre; Bak1 -/-; Bax flox/mice to cultures of irradiated bone marrow KSL cells promoted the recovery of total cells and CFCs in 7-d culture, whereas bone marrow serum from Tie2Cre; Bak1 -/-; Bax flox/+ mice had no beneficial effect (Supplementary Fig. 1a) .
To identify paracrine factors in the bone marrow of Tie2Cre; Bak1 -/-; Bax flox/mice that might contribute to the radioprotection of hematopoietic stem and progenitor cells in vivo, we assessed cytokine levels using a cytokine array on the bone marrow serum from Tie2Cre; Bak1 -/-; Bax flox/-, Tie2Cre; Bak1 -/-; Bax flox/+ and wild-type C57BL/6 mice before and after 750-cGy TBI. Within the list of cytokines that we described to be significantly enriched in bone marrow serum from Tie2Cre; Bak1 -/-; Bax flox/compared to Tie2Cre; Bak1 -/-; Bax flox/+ mice 14 , EGF was approximately 18-fold increased in concentration in the bone marrow of irradiated Tie2Cre; Bak1 -/-; Bax flox/mice compared to irradiated Tie2Cre; Bak1 -/-; Bax flox/+ mice (Fig. 1b) . EGF was also expressed at threefold higher levels in Bak1 -/-; Bax flox/compared to Bak1 -/-; Bax flox/+ endothelial cells ( Fig. 1b) . Furthermore, we did not detect EGF by ELISA of supernatants of bone marrow KSL cells from Tie2Cre; Bak1 -/-; Bax flox/mice (data not shown), suggesting that EGF is not produced in an autocrine manner by bone marrow stem and progenitor cells. Notably, Tie2Cre; Bak1 -/-; Bax flox/mice had an increased density of mouse endothelial cell antigen (MECA) + vessels in the bone marrow compared to Tie2Cre; Bak1 -/-; Bax flox/+ or C57BL/6 mice ( Supplementary Fig. 1b ). Therefore, the increased concentrations of EGF in the bone marrow serum of Tie2Cre; Bak1 -/-; Bax flox/mice compared to the controls may be due, in part, to the increased density of EGF-secreting bone marrow endothelial cells in Tie2Cre; Bak1 -/-; Bax flox/mice.
We next performed fluorescence-activated cell sorting (FACS) analysis to determine whether EGFR is expressed by wild-type bone marrow HSCs and progenitor cells. Less than 2% of bone marrow Lin + and Lincells expressed EGFR, but 7.9% of bone marrow KSL cells and 9.2% of bone marrow signaling lymphocytic activation molecule family (SLAM) + KSL cells, which are enriched for long-term HSCs 1 , expressed EGFR ( Fig. 1c) . EGFR surface expression increased fourfold and sixfold in bone marrow KSL and SLAM + KSL cells, respectively, at 4 h after 300-cGy irradiation ( Fig. 1c,d) , indicating that EGFR expression is induced in HSCs after irradiation. After EGF treatment, EGFR phosphorylation levels were increased in bone marrow KSL cells and bone marrow SLAM + KSL cells in vitro and in bone marrow KSL cells in vivo ( Fig. 1e) , demonstrating that EGFR is functional in bone marrow hematopoietic stem and progenitor cells.
We next performed gain-of-function studies to determine whether treatment of irradiated bone marrow KSL cells with EGF could support bone marrow stem and progenitor cell regeneration in vitro. When we added 20 ng ml -1 EGF to irradiated (300 cGy) bone marrow KSL cells cultured with cytokines (thrombopoietin, stem cell factor, Flt-3 ligand (TSF)), we found significant increases in the recovery of CFCs and CFU-S12 compared to cultures with cytokines alone (Fig. 1f) . The addition of EGF to noncontact FL/+ endothelial cell cultures of irradiated bone marrow KSL cells also increased CFC and CFU-S12 recovery compared to culture with FL/+ endothelial cells alone, whereas the addition of EGF-specific antibody to FL/endothelial cell cultures caused a substantial decrease in the recovery of CFC and CFU-S12 compared to FL/-endothelial cell cultures alone ( Supplementary Fig. 2) . These data suggest that FL/-endothelial cell-mediated regeneration of irradiated bone marrow progenitor cells is dependent on EGF. Using competitive repopulation assays, we also found that mice transplanted with the product of of irradiated, EGF-treated bone marrow CD34 -KSL cells showed threefold and fivefold higher donor hematopoietic cell engraftment at 8 and 12 weeks after transplant, respectively, compared to mice transplanted with the progeny of cytokine cultures alone ( Fig. 1g) .
Treatment of nonirradiated bone marrow KSL cells with EGF in vitro also caused a significant expansion of bone marrow KSL cells and CFU-S12 compared to the progeny of cytokine cultures alone ( Fig. 1h) . Mice competitively transplanted with the progeny of bone marrow CD34 -KSL cells cultured with cytokines plus EGF showed more than tenfold increased donor hematopoietic cell repopulation at 12 weeks after transplant compared to mice transplanted with the progeny of bone marrow CD34 -KSL cells cultured with cytokines alone (Fig. 1h) . These results suggest that EGF also promotes the maintenance of nonirradiated HSCs in culture.
EGF treatment promotes HSC regeneration in vivo
To determine whether EGF treatment can promote HSC regeneration in vivo, we measured hematopoietic reconstitution in C57BL/6 mice after 700-cGy TBI and subsequent intraperitoneal treatment with EGF or saline (control) beginning at 2 h after irradiation and then daily for 7 d ( Fig. 2a) . At day 7 after TBI, the EGF-treated mice had increased bone marrow cellularity compared to controls ( Fig. 2b) , as well as significantly increased numbers of bone marrow cells, bone marrow KSL cells, CFCs and CFU-S12 ( Fig. 2b-d) .
To determine whether treatment with EGF can rescue the functional bone marrow HSC pool in irradiated mice, we competitively transplanted lethally irradiated (CD45.1 + ) recipient mice with bone marrow cells from nonirradiated donor mice or from donor mice irradiated with 700 cGy and treated with either EGF or saline (CD45.2 + ). At 12 weeks after transplant, mice transplanted with 5 × 10 5 bone marrow cells from nonirradiated donors showed high donor-cell engraftment in the bone marrow (mean, 74.9%; Fig. 2e ). Conversely, mice transplanted with the same dose of bone marrow cells from irradiated and saline-treated donors demonstrated much lower donorcell engraftment (mean, 0.4%). Notably, mice transplanted with an identical dose of bone marrow cells from irradiated and EGF-treated mice showed significantly increased donor-cell engraftment (mean, 8.5%) compared to mice transplanted with bone marrow from irradiated and saline-treated donors ( Fig. 2e) . This difference in total engraftment was a function primarily of increased donor myeloid cell recovery in the EGF treatment group, suggesting that EGF treatment may have specifically augmented the recovery of short-term HSCs with myeloid reconstituting potential ( Fig. 2e) . We also found a close correspondence between total donor-cell engraftment and donorcell chimerism within bone marrow KSL cells in each group of mice ( Fig. 2e,f) 16 . Donor-cell engraftment within bone marrow KSL cells in recipients of bone marrow cells from irradiated and EGF-treated mice was sixfold higher than that in recipients of bone marrow cells from irradiated and saline-treated mice but was approximately 11% of the engraftment observed in mice transplanted with nonirradiated bone marrow cells. Therefore, although EGF treatment significantly increased the recovery of bone marrow HSCs after TBI, it did not fully restore HSC function compared to nonirradiated donor mice. npg a r t i c l e s nature medicine VOLUME 19 | NUMBER 3 | MARCH 2013 2 9 7
We also performed competitive secondary transplants in which we transplanted bone marrow cells from primary recipient mice into lethally irradiated syngeneic mice ( Fig. 2a) . At 12 weeks after transplant, secondary recipient mice receiving cells from the nonirradiated donor group showed high donor-cell engraftment (mean, 53.4%; Fig. 2g ). Conversely, mice receiving cells from the irradiated and saline-treated donor group had very low donor-cell engraftment (mean, 0.5%). Secondary recipients receiving cells from the irradiated npg a r t i c l e s and EGF-treated donor group showed significantly higher total and multilineage donor engraftment (mean, 24%; Fig. 2g ) compared to mice receiving cells from the irradiated and saline-treated donor group. Secondary recipient mice receiving cells from the irradiated and EGF-treated donor group showed a corresponding increase in donor-cell chimerism within bone marrow KSL cells compared to mice receiving cells from the irradiated and saline-treated donor group (Fig. 2h) . These results suggest that EGF treatment promotes the recovery of long-term HSCs in mice after TBI.
EGFR inhibition impairs HSC regeneration in vivo
To determine whether EGFR inhibition can suppress HSC regeneration in vivo, we irradiated mice with 700 cGy and then treated them with erlotinib, an EGFR antagonist, or water (control) by oral gavage from day 0 to day 14 ( Fig. 3a) . At day 7, both the erlotinib-treated and control mice showed depletion of bone marrow stem and progenitor cells (data not shown). At day 14, irradiated control mice showed recovery of bone marrow cellularity, CFCs and CFU-S12, whereas erlotinib-treated mice showed depletion of bone marrow CFCs and CFU-S12 (Fig. 3b,c) . The erlotinib-treated mice also had a deficit in short-term and longer-term HSCs after TBI as compared to irradiated control mice as measured by competitive repopulation assay (Fig. 3d) .
These results suggest that EGFR inhibition impairs hematopoietic stem and progenitor cell regeneration after TBI.
To determine whether EGFR signaling is involved in mediating the radioprotection we observed in Tie2Cre; Bak1 -/-; Bax flox/mice 14 , we administered erlotinib or water (control) to Tie2Cre; Bak1 -/-; Bax flox/mice beginning 3 d before 300-cGy TBI and evaluated bone marrow HSC and progenitor cell content at 2 h after TBI (Fig. 3e) . Erlotinib-treated Tie2Cre; Bak1 -/-; Bax flox/mice had significantly decreased numbers of bone marrow KSL cells and CFU-S12 after TBI compared to control irradiated Tie2Cre; Bak1 -/-; Bax flox/mice (Fig. 3f) . These decreases corresponded with decreased EGFR phosphorylation in bone marrow KSL cells in the erlotinib-treated Tie2Cre; Bak1 -/-; Bax flox/mice (Fig. 3g) . Irradiated Tie2Cre; Bak1 -/-; Bax flox/mice showed relative protection of bone marrow HSCs with multilineage repopulating capacity after TBI (Fig. 3h) . Conversely, erlotinib-treated irradiated Tie2Cre; Bak1 -/-; Bax flox/mice had a marked deficit in bone marrow HSCs capable of multilineage reconstitution in vivo (Fig. 3h) . These results suggest that EGFR signaling is important for the radioprotection of bone marrow stem and progenitor cells in Tie2Cre; Bak1 -/-; Bax flox/mice.
EGFR deficiency inhibits hematopoietic recovery after TBI Erlotinib has been shown to inhibit kinases other than EGFR, including JAK2 and Src kinases 17, 18 . To determine whether the effects of erlotinib on HSCs were specific to EGFR or were through off-target effects, we generated VavCre; Egfr flox/flox (Egfr flox/flox ) and VavCre;
Egfr +/+ (Egfr +/+ ) mice and verified the lack of EGFR mRNA expression in bone marrow lineage-negative (Lin -) cells (Fig. 4a) . We cultured bone marrow Lincells from Egfr flox/flox or Egfr +/+ mice in cytokine medium for 72 h and found decreased total cell growth and CFC production in the EGFR-deficient cells (Fig. 4b) . Treatment of Egfr flox/flox bone marrow Lincells with erlotinib caused no significant effect on total cell expansion or CFC production compared to Egfr flox/flox bone marrow Lincells cultured with cytokines alone (Fig. 4c) . Conversely, erlotinib treatment of Egfr +/+ bone marrow Lincells decreased total cell expansion and CFC production compared to Egfr +/+ bone marrow Lincells cultured with cytokines alone or compared to Egfr flox/flox bone marrow Lincells cultured with erlotinib. These data suggest that erlotinib acts specifically on EGFR in bone marrow progenitor cells.
We also compared the in vivo recovery of bone marrow hematopoietic stem and progenitor cells in Egfr +/+ and VavCre; Egfr flox/+ (Egfr flox/+ ) mice after 500-cGy TBI. At baseline, Egfr flox/+ mice showed decreased EGFR expression in bone marrow Lincells relative to Egfr +/+ mice (Fig. 4d) and had no differences in complete blood counts or bone marrow CFCs compared to Egfr +/+ mice (Fig. 4e,f) . However, at day 7 after TBI, Egfr flox/+ mice had fivefold decreased bone marrow CFC content and 30-fold decreased numbers a r t i c l e s 3 0 0 VOLUME 19 | NUMBER 3 | MARCH 2013 nature medicine of bone marrow SLAM + KSL cells compared to Eg fr +/+ mice (Fig. 4g) . These data suggest that EGFR may be necessary for normal bone marrow stem and progenitor cell regeneration after TBI.
EGF induces HSC cycling after irradiation
Activation of EGFR can promote both cell proliferation and survival after injury 19, 20 . We therefore tested whether EGF treatment modulates HSC cycle status after irradiation. We irradiated bone marrow KSL cells with 300 cGy and then treated them in vitro with cytokines alone or cytokines plus EGF. At baseline, more than 90% of the bone marrow KSL cells were in G 0 /G 1 (Fig. 5a) . At 72 h after irradiation, EGF treatment of irradiated bone marrow KSL cells caused a significant increase in the number of cells in G 2 /S/M and a corresponding decrease in the number of cells in G 0 compared to cytokine treatment alone (Fig. 5a) . EGF treatment had comparable proliferative effects on irradiated bone marrow KSL cells from Tie2Cre; Bak1 -/-; Bax flox/mice (Supplementary Fig. 3a) . EGF treatment of mice for 7 d after 700-cGy TBI also significantly increased BrdU incorporation in bone marrow KSL cells compared to saline-treated irradiated mice (Fig. 5b) . EGFR can mediate cell proliferation through activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-AKT pathways 21, 22 . In irradiated bone marrow KSL cells, EGF treatment did not alter MAPK phosphorylation (data not shown) but did increase AKT phosphorylation (Fig. 5c) . This induction of AKT in response to EGF treatment corresponded with increased CFC recovery in EGF-treated bone marrow KSL cells after irradiation (Fig. 5c) . Treatment of irradiated bone marrow KSL cells with Ly294002, a PI3K inhibitor, blocked EGF-mediated AKT phosphorylation and inhibited bone marrow progenitor cell recovery in response to EGF (Fig. 5c) . Irradiated bone marrow KSL cells treated with EGF and Ly294002 also showed significantly decreased cell cycling compared to KSL cells treated with EGF alone (Fig. 5c) . These data suggest that EGF-driven effects on HSC cycling and progenitor cell recovery are mediated, at least in part, by activation of the PI3K-AKT pathway.
EGF inhibits HSC apoptosis by repression of PUMA
We performed annexin and 7-aminoactinomycin D (7-AAD) staining to assess the effects of EGF on HSC survival after irradiation. At 72 h after 300-cGy irradiation, EGF-treated cultures contained twofold decreased numbers of annexin-positive KSL cells compared to cytokine cultures (Fig. 5d) . C57BL/6 mice irradiated with 700 cGy and then treated with EGF for 7 d also contained fourfold decreased numbers of annexin-positive bone marrow hematopoietic cells compared to salinetreated controls (Fig. 5d) . EGF treatment also decreased the numbers of annexin-positive cells in cultures of irradiated bone marrow KSL cells from Tie2Cre; Bak1 -/-; Bax flox/mice (Supplementary Fig. 3b ). This result suggests that EGF may mediate HSC survival after irradiation through additional mechanisms, such as DNA repair, that are not directly related to inhibition of apoptosis 23 .
PUMA is an essential mediator of radiation-induced hematopoietic toxicity 24, 25 . Because EGF promoted HSC survival after irradiation, we examined whether EGF causes such effects through inhibition of PUMA. PUMA mRNA expression increased significantly in bone marrow HSCs from Trp53 +/+ mice after 300-cGy irradiation, whereas PUMA mRNA expression did not change in irradiated HSCs from Trp53 -/mice, indicating that PUMA induction in HSCs is p53 dependent (Fig. 5e) . EGF treatment repressed radiation-induced PUMA expression in bone marrow KSL cells from Trp53 +/+ mice but had no effect on those from Trp53 -/mice (Fig. 5e) . PUMA protein expression in bone marrow KSL cells correspondingly increased in response to radiation in a p53-dependent manner, and EGF treatment significantly decreased PUMA protein expression in these cells after irradiation (Fig. 5e) .
Bone marrow KSL cells from PUMA-deficient mice had a lower percentage of apoptotic cells and increased CFC content at 72 h after 300-cGy irradiation compared to PUMA-expressing bone marrow KSL cells (Fig. 5f-h) . EGF treatment increased HSC survival and CFC regeneration in PUMA-expressing KSL cell cultures after irradiation but had no effect on HSC survival or CFC production in PUMAdeficient KSL cell cultures after irradiation (Fig. 5f-h) . These results suggest that EGF-mediated inhibition of radiation-induced HSC apoptosis is dependent on inhibition of PUMA. 
EGF treatment improves the survival of lethally irradiated mice
To test whether EGFR signaling affects the survival of mice after TBI, we treated C57BL/6 mice with 10 µg per g body weight erlotinib or water (control) from day -3 to day +14 after 700-cGy TBI. Fifty-three percent (8 of 15) of control irradiated mice remained alive through day +30. In contrast, none (0 of 15) of the erlotinib-treated mice survived beyond day +27 (Fig. 6) . We irradiated an additional group of C57BL/6 mice with 700 cGy and treated them with either 0.5 µg per g body weight EGF or saline intravenously for 7 d beginning 2 h after TBI. Fifty-seven percent of saline-treated mice (8 of 14) survived through day +30 (Fig. 6) . Conversely, 93% of EGF-treated mice (14 of 15) remained alive through day +30. These results suggest that pharmacologic modulation of EGFR signaling alters survival after TBI. 
DISCUSSION
Recent studies suggest that hematopoietic regeneration in vivo is regulated by bone marrow endothelial cells [4] [5] [6] . However, the mechanisms through which these cells regulate hematopoietic regeneration remain largely unknown. Identification of the mechanisms that govern hematopoietic regeneration could have broad implications for the treatment of patients receiving myelosuppressive chemotherapy or radiotherapy or those undergoing stem cell transplantation 26 . Here we demonstrate that EGF, which we identified using a screen of bone marrow serum from radioprotected mice bearing deletion of Bak and Bax in TIE2-expressing endothelial cells, mitigates radiation injury to HSCs, and systemic administration of EGF can improve the survival of irradiated mice. Of note, EGF is a mitogen for nonhematopoietic cells that are affected by radiation injury (for example, intestinal epithelium), and such effects may have contributed to the EGF-mediated improvement in mouse survival. Nonetheless, our results suggest that systemic administration of EGF could have therapeutic potential to accelerate hematopoietic recovery in patients who have received TBI, as well as in victims of acute radiation sickness 27, 28 . In that regard, it is worth noting that EGF treatment caused a significant enhancement in myeloid reconstitution in primary transplanted mice, suggesting a specific effect on short-term HSCs with myeloid repopulating potential. Furthermore, whereas EGF treatment was associated with improved multilineage hematopoietic reconstitution in secondary transplanted mice, stronger myeloid recovery was observed, and T cell reconstitution was relatively low. This skewing toward myeloid recovery at the expense of T lymphoid recovery in recipients of bone marrow cells from irradiated donors mimics some aspects of the HSC aging phenotype and may reflect TBI-mediated DNA damage to the HSC pool 29, 30 . As erlotinib has recently been shown to mediate cellular effects through inhibition of targets other than EGFR 17,18 , we used VavCre; Egfr flox/flox mice to determine the specific role of EGFR in regulating the hematopoietic response to radiation. In vitro studies demonstrated that erlotinib treatment had no effect on EGFR-deficient hematopoietic cells in culture, whereas erlotinib treatment of Egfr +/+ hematopoietic cells significantly inhibited both cell expansion and CFC production in culture. Therefore, erlotinib acts specifically through EGFR inhibition to diminish hematopoietic progenitor cell recovery in our model. Notably, VavCre; Egfr flox/+ mice, which are heterozygous for EGFR expression, had significantly decreased bone marrow HSC and progenitor cell recovery early after TBI compared to VavCre; Egfr +/+ mice, which retain both EGFR alleles. These results suggest that EGFR signaling has an important role in regulating hematopoietic regeneration after radiation injury.
Gamma radiation causes direct and indirect DNA damage that can result in cell-cycle arrest or apoptosis of hematopoietic progenitor cells 31 . In the presence of radiation-induced DNA damage, cell-cycle arrest can occur through p53-dependent or -independent mechanisms 32, 33 . Cell-cycle arrest of hematopoietic cells can be overridden by treatment with cytokines 34 , and cytokine-mediated induction of hematopoietic progenitor cell proliferation early after radiation exposure may have beneficial effects toward promoting short-term hematopoietic recovery and improved near-term survival 10, 35, 36 . Although the mechanism behind these effects is not clear, cytokine treatment may induce synchronous entry of hematopoietic stem and progenitor cells into late S phase, a more radioresistant phase of the cell cycle 36, 37 . Cytokine-driven differentiation of HSCs into myeloerythroid progenitor cells could also provide short-term benefit, as systemic infusion of myeloerythroid progenitor cells alone can completely radioprotect mice after lethal-dose TBI 38 . In nonhematopoietic tissues, EGFR signaling can regulate cell proliferation in a context-dependent manner, producing both cell-cycle arrest and augmented proliferation 22, 39 .
Here we show that EGF treatment induces early HSC cycling after radiation exposure and that this effect is mediated through activation of the PI3K-AKT pathway. Although EGF can modulate radiation responses through additional mechanisms such as induction of DNA repair mechanisms 23 , our data suggest that EGF-mediated induction of HSC proliferation contributes to the early recovery of the hematopoietic progenitor pool after irradiation.
Deletion of PUMA has been shown to protect bone marrow hematopoietic stem and progenitor cells from radiation-induced death and confer a survival advantage in mice after TBI 24, 25 . We have shown that EGF treatment represses radiation-induced expression of PUMA in HSCs. Furthermore the effects of EGF are dependent largely on repression of PUMA. This result is consistent with previous studies that have shown that cytokines such as interkeukin-3 (IL-3) can inhibit PUMA expression in hematopoietic cells and that cytokine withdrawal mediates hematopoietic cell death in a PUMA-dependent manner 40, 41 . Of note, AKT, which is induced by EGF treatment of HSCs, was reported to suppress p53-dependent induction of PUMA and promote PUMA protein destabilization in leukemia cells 42 . Although our results suggest that EGF-mediated inhibition of HSC apoptosis is dependent on repression of PUMA, it remains possible that changes in the expression of other cell-cycle regulators (for example, induction of p21) in PUMA-deficient mice 43 may contribute to the effects of PUMA deficiency on the regenerative effects of EGF.
EGF has been implicated in regulating cell survival and stem cell fate outside the hematopoietic system. EGF is an established mitogen and prosurvival factor for epithelial cells and endothelial cells, and mutations in EGFR can be tumorigenic [44] [45] [46] [47] [48] . EGF also regulates stem cell functions in nonhematopoietic tissues such as the brain and liver [49] [50] [51] . Previous studies have suggested that EGFR is not expressed in hematopoietic stem cells [52] [53] [54] , although these studies did not use multiparametric flow cytometry to isolate bone marrow HSCs as we performed here. Although EGFR was recently shown to be expressed in bone marrow c-Kit + Linprogenitor cells 55, 56 , EGF was not previously known to regulate HSC self renewal or regeneration. In a previous study, the addition of EGF to stromal cell cocultures was shown to inhibit hematopoietic progenitor cell growth in vitro, but these effects could be attributed to indirect effects on stromal cells 57 . It was also recently reported that EGFR inhibition facilitates granulocyte colonystimulating factor (GCSF)-mediated mobilization of hematopoietic progenitor cells in mice 55 . In this study, no effects were demonstrated in the absence of G-CSF and no effects on HSC content, proliferation or function were described 55 .
We have elucidated a previously unknown function of EGF in promoting HSC regeneration after radiation-induced myelosuppression. We show that bone marrow HSCs express functional EGFR and that EGF acts directly on HSCs to increase HSC cycling and survival after irradiation. These observed effects of EGF on HSC growth are comparable to those described for fibroblast growth factor 1 (FGF1), which also activates PI3K-AKT signaling, suggesting a possible convergence of action of EGF and FGF1 on crucial signaling pathways in HSCs 58, 59 . Translationally, these results suggest that EGF may have therapeutic potential in patients undergoing hematopoietic cell transplant who receive TBI-based conditioning before transplant. In light of a recent report of a deleterious bystander effect of TBIinduced reactive oxygen species on transplanted donor HSCs, it will be interesting to determine whether EGF administration can ameliorate such effects to augment hematopoietic reconstitution 60 . EGF also has potential utility for the treatment of acute radiation sickness, which can cause life threatening bone marrow failure and for which few treatments exist.
METHODS
Methods and any associated references are available in the online version of the paper. a r t i c l e s Minneapolis, MN) or 200 µl PBS starting at 2 h after TBI on day 0 through day +7. Competitive repopulation assays were also performed using bone marrow cells from nonirradiated C57BL/6 mice as positive controls to compare with irradiated and saline-treated and irradiated and EGF-treated donors. Competitive repopulation assays were also performed with bone marrow harvested at day +14 from donor C57BL/6 mice (CD45.2 + ) that had been irradiated with 700-cGy TBI and gavaged daily with 10 µg per g body weight erlotinib (Genentech, San Francisco, CA) or 150 µl water beginning on day 0 and continued through day +14. Donor bone marrow cells were injected by tail vein into recipient B6.SJL mice (CD45.1 + ) at a dose of 5 × 10 5 cells with a competing dose of host 1 × 10 5 bone marrow mononuclear cells (MNCs). Primary total CD45.2 + donor cell engraftment, multilineage engraftment and donor chimerism within bone marrow KSL cells were measured in recipient mice at 12 weeks after transplant. Secondary competitive repopulation assays into lethally irradiated B6.SJL mice were performed using 75% of the total whole bone marrow cells from a group of primary recipient mice, transplanted as described above, and a competing dose of host 1 × 10 5 bone marrow MNCs. Measurement of donor cell chimerism within the bone marrow KSL population was performed at 12 weeks after transplantation in primary and secondary transplanted mice, as previously described 16 .
Tie2Cre; Bak1 -/-; Bax flox/mice were gavaged daily with 10 µg per g body weight erlotinib or water starting day -3 and given 300-cGy TBI on day 0. Erlotinib administration continued until the time point of donor bone marrow cell collection and analysis. Tie2Cre; Bak1 -/-; Bax flox/bone marrow cells were injected by tail vein into recipient CD45.1 + mice at a cell dose of 3 × 10 5 cells with a competing dose of host 1 × 10 5 CD45.1 + cells. Multilineage hematopoietic reconstitution was measured in the peripheral blood of recipient mice by flow cytometry at weeks 4, 8 and 12 after transplant. For survival studies with erlotinib administration, C57BL/6 mice were exposed to 700-cGy irradiation and then given 10 µg per g body weight erlotinib or water starting on day -3 and continuing daily through day +14. Age-matched adult C57BL/6 mice were also exposed to 700-cGy TBI and then given tail vein injections with 0.5 µg per g body weight EGF or saline beginning at +2 h after TBI and then daily through day +7. We chose 700 cGy for lethality studies because this radiation dose causes 50% lethality by day +30 in adult C57BL/6 mice at Duke University Medical Center (Cs137 irradiator).
Immunohistochemical analyses. Femurs were decalcified and embedded in optimal cutting temperature (OCT) medium (Sakura Finetek, Torrance, CA), as previously described, on day 7 or 14 after 700-cGy TBI with daily administration of EGF or erlotinib. Ten-micrometer sections were cut using the CryoJane tape system (Instrumedics Inc, Hackensack, NJ, USA). Femurs were stained with H&E or antibody to MECA-32 (1% dilution, catalog number 550563, BD) as previously described 4 to assess bone marrow cellularity and the bone marrow vasculature after irradiation. Images were obtained using an Axiovert 200 microscope (Carl Zeiss Microscopy, Thornwood, NY) or a Leica SP5 confocal microscope (Leica Microsystems Inc, Buffalo Grove, IL). Adobe Photoshop software (version 9.0.2, Adobe Systems, San Jose, CA) was used to quantify a positive signal as a measure of the total number of pixels 70, 71 .
Statistical analyses. Data are shown as means ± s.e.m. We used the Mann-Whitney test (two-tailed nonparametric analysis) for the majority of comparisons, along with the Student's t test (two-tailed or one-tailed distribution with unequal variance). Comparisons of overall survival were performed using a log-rank test.
